Business
Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for
About this update from Immunovant, Inc.
[{"type":"text","content":"NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, announced today that Pete Salzmann, Chief Executive Officer, will provide a corporate overview at the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27 in New York City.\n 9th Annual Global Healthcare ConferenceDate:Tuesday, February 25thTime:3:00pm Eastern TimeWebcast: The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com About Immunovant, Inc.Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. Contact:John Strumbos, Ph.D., MBAVice President, FinanceImmunovant, [email protected] \n\n\nSource: Immunovant","length":2933,"tagName":"div"}]